Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment
December 05, 2023 14:13 ET
|
Bsense Bio Therapeutics, Ltd.
NESS ZIONA, Israel, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Bsense Bio Therapeutics Ltd., a preclinical-stage biopharmaceutical company developing innovative small molecule drug candidates for sensory...
Bsense Announces Positive Topline Proof-of-Concept Preclinical Data that Supports the Development in Additional Sensory Hyperexcitability Related Disorders
December 06, 2021 10:00 ET
|
B Sense Bio Therapeutics, Ltd.
NESS ZIONA, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bsense Bio Therapeutics Ltd., a FutuRx portfolio biopharmaceutical company dedicated to developing novel therapeutics for treatment of sensory...